{Reference Type}: Journal Article
{Title}: Cefiderocol: Clinical application and emergence of resistance.
{Author}: Wang L;Zhu J;Chen L;Du H;
{Journal}: Drug Resist Updat
{Volume}: 72
{Issue}: 0
{Year}: 2024 Jan 18
{Factor}: 22.841
{DOI}: 10.1016/j.drup.2023.101034
{Abstract}: Antibacterial drug resistance of gram-negative bacteria (GNB) results in high morbidity and mortality of GNB infection, seriously threaten human health globally. Developing new antibiotics has become the critical need for dealing with drug-resistant bacterial infections. Cefiderocol is an iron carrier cephalosporin that achieves drug accumulation through a unique "Trojan horse" strategy into the bacterial periplasm. It shows high antibacterial activity against multidrug-resistant (MDR) Enterobacteriaceae and MDR non-fermentative bacteria. The application of cefiderocol offers new hope for treating clinical drug-resistant bacterial infections. However, limited clinical data and uncertainties about its resistance mechanisms constrain the choice of its therapeutic use. This review aimed to summarize the clinical applications, drug resistance mechanisms, and co-administration of cefiderocol.